Abstract
A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have